Europe's regulator recommends Mounjaro for weight management

On November 10, 2023, the European Medicines Agency's human medicines committee recommended widening the approval of Eli Lilly's diabetes drug Mounjaro to include chronic weight management ^[1][2]. The recommendation now goes to the European Commission, which makes the final call but almost always follows the EMA's guidance ^[2].

Mounjaro is the brand name for tirzepatide, a drug that has been sold in Europe to treat type 2 diabetes since 2022 ^[1]. Unlike in the United States, where regulators created a second brand name, Zepbound, for the weight-loss version of the same molecule, the European recommendation keeps tirzepatide under the single Mounjaro name for both uses ^[1]. The extension of the existing marketing authorization, rather than a new one, is the mechanism EU regulators chose.

The European move came just two days after U.S. and UK regulators both cleared tirzepatide for weight loss, on November 8, 2023 ^[1][2]. In the U.S., the newly approved weight-loss version was set to appear as Zepbound on pharmacy shelves later that same month, while Lilly said it would reach UK patients "sooner rather than later" ^[1]. Tirzepatide belongs to a class of drugs, sometimes called GLP-1 medicines, that also affect other hormone receptors and have produced significant weight loss in trials, according to reporting on the decision ^[2].

Before this recommendation, doctors in Europe, as in the U.S. and UK, had already been prescribing Mounjaro off-label for weight loss even though it was only formally approved for diabetes ^[1][2]. A specific weight-management approval is expected to make that kind of prescribing more straightforward going forward, according to the reporting ^[2].

Why it matters for patients

For patients in EU countries, this recommendation is a step toward being able to get tirzepatide prescribed specifically for weight management rather than relying on an off-label diabetes prescription, which can complicate insurance coverage, dosing guidance, and prescribing comfort for doctors ^[1][2]. Because Europe is keeping one brand name, Mounjaro, for both diabetes and weight uses, patients and pharmacists there will not have to distinguish between two separately branded products the way U.S. patients now do with Mounjaro (diabetes) and Zepbound (weight loss) ^[1].

The sources do not specify what dosing, price, or reimbursement terms might apply once the European Commission finalizes the change, so those details are not yet known. It is also not stated in the sources how soon after the CHMP recommendation the European Commission is expected to issue its final decision, only that such decisions almost always follow the committee's guidance ^[2].

What happens next

The European Commission still needs to issue a final decision on the expanded marketing authorization; the sources note this step is pending but do not give a date ^[1][2]. In the U.S. and UK, where approvals for weight-loss use had already been granted two days earlier, on November 8, 2023, Zepbound was expected in U.S. pharmacies later in November 2023, and Lilly said UK availability would follow soon ^[1]. The sources do not report a specific timeline for when Mounjaro would be available with the expanded weight-management label in EU countries once the European Commission acts.